Inovio initiates Phase III trial of VGX-3100 to treat HPV-related cervical pre-cancer

Inovio Pharmaceuticals has initiated its Phase III REVEAL clinical programme of VGX-3100 for the treatment of cervical dysplasia associated with human papillomavirus (HPV), following a clinical hold removal by the US Food and Drug Administration (FDA …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news